Immunome Inc. (IMNM) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$24.01

From 52W high−19.64%

Volume3.88M

Market cap$2.72B

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataSep 18, 2026

Open

$24.01

From 52W high

−19.64%

Volume

3.88M

Market cap

$2.72B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−8.8x

P/E (TTM)

—

RSI (14)

35.7

MomentumView details →

1D Return

+0.17%

YTD Return

+9.64%

SummaryUpdated Jun 1, 2026

Immunome, Inc. (NASDAQ:IMNM) is a biopharmaceutical company founded in 2006 and headquartered in Exton, Pennsylvania. The company went public in October 2020 and focuses on discovering and developing antibody-based therapeutics for treating cancer and infectious diseases. Immunome leverages its proprietary antibody discovery platform to identify novel therapeutic targets and develop treatments that harness the immune system's power to fight disease.

Ask drillr about Immunome Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−8.8x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

5.2x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−48.43%

ROA (TTM)

−44.98%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

−100.00%

EPS YoY

+17.53%

FCF YoY

−17.68%

Revenue CAGR 3Y

−29.63%

EPS CAGR 3Y

+51.40%

EBITDA YoY

−38.17%

MomentumView details →

1D Return

+0.17%

YTD Return

+9.64%

1Y Return

+150.80%

RSI (14)

35.7

vs 50D SMA

−6.74%

vs 200D SMA

+4.15%

Capital & dividendView details →

Debt/Equity

0.01x

Current Ratio

15.08x

Quick Ratio

15.08x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.65

EPS Surprise

−26.51%

Beats (12Q)

4/12

Next Q EPS Est

−$0.60

Avg Surprise (4Q)

−8.98%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−254.32M

Op. CF (TTM)

−208.79M

Next earningsNov 5, 2026 →

Latest newsMore news →

Immunome dosed the first patient in a Phase 1 trial of IM-3050, an FAP-targeted radioligand therapy, for advanced solid tumors.62d ago

Immunome announced that the U.S. FDA accepted its New Drug Application for varegacestat for the treatment of adults with desmoid tumors.74d ago

Similar companies

NewAmsterdam Pharma Company N.V.NAMS Soleno Therapeutics, Inc.SLNO Beijing Luzhu Biotechnology Co., Ltd.02480.HK BioDlink International Company Limited01875.HK Genor Biopharma Holdings Limited06998.HK Disc Medicine, Inc.IRON Find similar companies →

Latest newsMore news →

Immunome dosed the first patient in a Phase 1 trial of IM-3050, an FAP-targeted radioligand therapy, for advanced solid tumors.62d ago Immunome announced that the U.S. FDA accepted its New Drug Application for varegacestat for the treatment of adults with desmoid tumors.74d ago